DR JOHN CAMPBELL ANALYSIS
Research published in the peer-reviewed journal JAMA, indicates the risk of developing myocarditis after receiving an mRNA COVID-19 vaccine (Pfizer and Moderna), could be higher than 84 times that of the background risk in the population.
The expected rates of myocarditis, used as a comparison throughout the study, were taken from 2017 to 2019 data, before the pandemic.
1,991 reported cases, with 1,626 being confirmed cases, between December 2021 and August 2021 of myocarditis were studied. All reported cases are taken from the Vaccine Adverse Event Reporting System (VAERS), run by the Center for Disease Control and Prevention (CDC).
Around 96% of these cases required hospitalisation.
82% of the studied myocarditis cases were Male (18% Female). Interestingly, boys and young men aged between 12 and 24 are at the highest risk of developing myocarditis post-vaccination, with the median age being 21 years and the highest instances of the condition occurring at 16 years.
So what is the overall risk of developing myocarditis, after an mRNA COVID-19 vaccination?
MYOCARDITIS RISK POST-VACCINATION
From the data provided by the study, 16 to 17-year-olds experienced the highest risk of developing myocarditis post-vaccination, according to Dr John Campbell.
This age group is 84.4 times more likely to develop the condition, after their first and second dose of mRNA vaccine (105.9 cases per million doses), when compared to the expected rate of myocarditis in that age group.
This increased risk factor could be much higher than the paper leads on, Dr Campbell says, due to the strict requirements needed to “medically confirm” a myocarditis case. Due to this, many people experiencing myocarditis symptoms post-vaccination were likely unreported to the VAERS.
He also believes some parts of the study are “misleading,” due to how the data has been presented. Meaning, the risk factor could be higher than the initially reported “133 times,” instead of his calculated 84.4 times, based on the data provided.
Older age groups (30+) are reportedly at “essentially no risk” of developing myocarditis – even before the pandemic began, he says. Although, the condition is not unheard of in older people.
It must be noted that the study does not indicate a definitive causal link between mRNA COVID-19 vaccination and myocarditis. But Dr Campbell believes that myocarditis (and pericarditis) “does seem to be unique to mRNA vaccines.”
WHO IS DR JOHN CAMPBELL?
Dr John Campbell is an ex-nurse educator turned famous YouTube COVID-19 research commentator and vaccine advocate. He has come under recent scrutiny from the BBC, due to his seemingly unbiased reporting on all sides of the COVID-19 discussion.
From vaccine benefits and adverse events, COVID-19 data and the mainstream media narrative, to the benefits of vitamin D and impacts of Ivermectin on the virus, Dr Campbell is known for taking on controversial topics of discussion.
With his channel boasting over 2.2 million subscribers and 411 million total views, Dr Campbell regularly has a wide range of experts from many different countries on to discuss these topics.
For further information regarding Dr Campbell’s analysis of the myocarditis and mRNA COVID-19 vaccine study, please visit his YouTube channel:
WHAT IS MYOCARDITIS?
Myocarditis occurs “when the heart muscle (myocardium) becomes inflamed,” according to John Hopkins Medicine. In other words – an inflamed heart; a condition at the forefront of the vaccine adverse event discussion.
Symptoms include chest pain, fatigue, rapid or abnormal heart rhythm (arrhythmia), shortness of breath and swelling of the legs. Death is rare, but left untreated, “Sudden death can occur as a result of dangerous arrhythmias caused by myocarditis,” according to the Myocarditis Foundation.
Most cases are mild and resolve quickly, typically being treated with anti-inflammatories, beta-blockers, corticosteroids, diuretics or angiotensin-converting enzyme (ACE) inhibitors. But the condition can lead to requiring more invasive treatments, like a pacemaker or heart transplant.
Moreover, though the increased risk of myocarditis is linked to mRNA vaccination, it is also linked to COVID-19 and other types of viral infections. However, a number of studies have concluded that the “true epidemiology of COVID-19 myocarditis is difficult to establish.” With others suggesting that COVID-19 is a “much bigger risk” to the heart than vaccination-induced myocarditis.
The study authors concluded by noting that myocarditis is a:
“rare but serious adverse event that can occur after mRNA-based COVID-19 vaccination … the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination.”